Skip to main content
Skip to main menu Skip to spotlight region Skip to secondary region Skip to UGA region Skip to Tertiary region Skip to Quaternary region Skip to unit footer


Tianxi Cai

Harvard University

Clinical trials that evaluate treatment benefit focus primarily on estimating the average benefit. However, a treatment reported to be effective may not be beneficial to all patients. For example, the benefit of giving chemotherapy prior to hormone therapy with Tamoxifen in the adjuvant treatment of postmenopausal women with lymph node negative breast cancer depends on the ER-status. Due to the toxicity of chemotherapy, it is crucial to identify patients who will and will not benefit from chemotherapy. This gives rise to the need of accurately predicting benefit based on important markers. In this research, we propose systematic, two-stage estimation and calibration procedures to infer about subgroup specific treatment differences to optimally future patient's disease management and treatment selections. Procedures to evaluate and compare personalized treatment assignment strategies will also be discussed. The new proposals are illustrated with the data from an AIDS clinical trial and a randomized trial for treating patients with stable coronary heart disease.


More information on Tianxi Cai may be found at


This Colloquium is sponsored jointly by the University of Georgia Department of Statistics and the University of Georgia Department of Epidemiology and Biostatistics.

Support us

We appreciate your financial support. Your gift is important to us and helps support critical opportunities for students and faculty alike, including lectures, travel support, and any number of educational events that augment the classroom experience. Click here to learn more about giving.

Every dollar given has a direct impact upon our students and faculty.